CARISMA THERAP (CARM)
(Delayed Data from NSDQ)
$0.95 USD
-0.03 (-2.86%)
Updated Oct 1, 2024 04:00 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Carisma Therapeutics Inc. (CARM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.60 | $10.00 | $6.00 | 700.00% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Carisma Therapeutics Inc. comes to $7.60. The forecasts range from a low of $6.00 to a high of $10.00. The average price target represents an increase of 700% from the last closing price of $0.95.
Analyst Price Targets (5 )
Broker Rating
Carisma Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/26/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Strong Buy |
4/11/2024 | BTIG | Justin R Zelin | Not Available | Strong Buy |
4/11/2024 | Capital One Securities | Naureen Quibria | Strong Buy | Strong Buy |
3/15/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
3/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $7.60 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | -0.37 |
CARM FAQs
Carisma Therapeutics Inc. (CARM) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for Carisma Therapeutics Inc. (CARM) is $7.60. The current on short-term price targets is based on 2 reports.
The forecasts for Carisma Therapeutics Inc. (CARM) range from a low of $6 to a high of $10. The average price target represents a increase of $700.00 from the last closing price of $.95.
The current UPSIDE for Carisma Therapeutics Inc. (CARM) is 700.00%
Based on short-term price targets offered by five analysts, the average price target for Carisma Therapeutics Inc. comes to $7.60. The forecasts range from a low of $6.00 to a high of $10.00. The average price target represents an increase of 700% from the last closing price of $0.95.